Damora Therapeutics (DMRA)
NASDAQ:DMRA
Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$26.60
-$0.21(-3.82%)
At close: 4:00 PM EST
$26.60
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.26M
Market Cap
$1.31B
Enterprise Value$786.91M
Total Cash (Recent Filing)$532.90M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 05, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-172.21
Shares Outstanding61,553,192
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.57K
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$43.14Price Target Upside62.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Financial FlexibilityVery low debt and minimal leverage materially reduce near-term solvency risk and preserve financial optionality. For a pre-commercial biotech this supports continued R&D investment, gives management flexibility on timing and structure of future financings, and lowers default risk while advancing clinical programs.
Experienced Leadership And Board OverhaulInstalling a proven CEO and industry-experienced directors strengthens execution, strategic planning, and capital-markets credibility. Over time this raises the odds of disciplined clinical development, better partner or financing access, and improved governance—key durable drivers for advancing lead programs to value-inflecting milestones.
Improving Cash-burn TrajectoryA meaningful reduction in annual cash outflow signals improved operational discipline or integration benefits post-transaction. Sustained lower burn lengthens runway, reduces near-term financing pressure, and increases the probability management can reach clinical inflection points without urgent, highly dilutive funding.
Bears Say
No Revenue And Widening Net LossesAbsence of revenue combined with a large, volatile loss base reflects a pre-commercial biotech still burning capital to fund R&D and integration costs. Persistently negative profitability increases reliance on external capital, delays self-sustaining operations, and elevates execution risk tied to clinical outcomes and milestone timing.
Negative Cash Generation; Funding DependenceConsistent negative operating and free cash flow makes the company dependent on equity/debt markets or partners for runway. This structural financing need can force dilutive financings, constrain strategic optionality, and expose the company to market windows and investor sentiment unrelated to operational progress.
Capital-structure Swings And Dilution RiskMaterial swings in equity indicate prior dilution and a history of financing activity; combined with no revenue and heavy losses, future capital raises are likely. Recurrent dilution can erode existing shareholder value, complicate long-term investor alignment, and pressure management to prioritize financing outcomes over operational optimization.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics’s price range in the past 12 months?
Damora Therapeutics lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics’s market cap?
Damora Therapeutics’s market cap is $1.31B.
When is Damora Therapeutics’s upcoming earnings report date?
Damora Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 46 days.
How were Damora Therapeutics’s earnings last quarter?
Damora Therapeutics released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.232.
Is Damora Therapeutics overvalued?
According to Wall Street analysts Damora Therapeutics’s price is currently Undervalued.
Does Damora Therapeutics pay dividends?
Damora Therapeutics does not currently pay dividends.
What is Damora Therapeutics’s EPS estimate?
Damora Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Damora Therapeutics have?
Damora Therapeutics has 61,553,192 shares outstanding.
What happened to Damora Therapeutics’s price movement after its last earnings report?
Damora Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went up 4.634%.
Which hedge fund is a major shareholder of Damora Therapeutics?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.14 (62.19% Upside)
$43.14 (62.19% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-122.40%
Trailing 12-Months
Asset Growth
3384.82%
Trailing 12-Months
Company Description
Damora Therapeutics
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$43.14
▲(62.19% Upside)
Technical Analysis
Ownership Overview
15.99% Insiders
6.66% Mutual Funds
61.80% Other Institutional Investors
14.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---